GlassScriptPhysician profile
Brian N Henry
NPI 1780669564
$3,079.86
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $1,024 · 2021: $30.32 · 2022: $1,234.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novus Surgical Solutions LLC | $1,200.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $389.34 | 2019-2020 | |
| Pfizer INC. | $215.51 | 2019-2022 | |
| Novo Nordisk INC | $215.35 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.31 | 2019-2021 | |
| Amgen INC. | $148.06 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $76.88 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.10 | 2019 | |
| Allergan, INC. | $68.36 | 2019-2020 | |
| Lilly USA, LLC | $63.67 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $51.84 | 2019-2020 | |
| Glaxosmithkline, LLC. | $51.63 | 2019-2020 | |
| Strongbridge US INC. | $46.70 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $41.15 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.37 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $32.16 | 2020 | |
| Abbott Laboratories | $28.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $27.28 | 2019 | |
| Antares Pharma, INC. | $19.66 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.18 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.23 | 2021 | |
| Genentech USA, INC. | $15.09 | 2019 | |
| Currax Pharmaceuticals LLC | $14.47 | 2020 | |
| Adlon Therapeutics L.P. | $13.81 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.84 | 2020 | |
| Ironshore Pharmaceuticals INC. | $11.37 | 2019 | |
| Neos Therapeutics, LP | $11.26 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $10.84 | 2019 | |
| Endogastric Solutions, INC | $7.35 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.